AI Article Synopsis
- Opioid-induced constipation (OIC) is a common and challenging side effect of opioid therapy that often does not respond well to standard laxatives.
- New medications called peripherally acting μ-opioid receptor antagonists, like methylnaltrexone, naloxegol, and alvimopan, show promise in treating OIC without interfering with pain relief.
- Alternative treatments also include combinations of oxycodone with naloxone to manage pain while addressing constipation, although some side effects like abdominal pain may occur.
Article Abstract
Opioid-induced constipation (OIC), a prevalent and distressing side effect of opioid therapy, does not reliably respond to treatment with conventional laxatives. OIC can be a treatment-limiting adverse event. Recent advances in medications with peripherally acting μ-opioid receptor antagonists, such as methylnaltrexone, naloxegol, and alvimopan, hold promise for treating OIC and thus extending the benefits of opioid analgesia to more chronic pain patients. Peripherally acting μ-opioid receptor antagonists have been clinically tested to improve bowel symptoms without compromise to pain relief, although there are associated side effects, including abdominal pain. Other treatment options include fixed-dose combination products of oxycodone analgesic together with naloxone.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5261842 | PMC |
| http://dx.doi.org/10.2147/PPA.S78042 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!